Cat. No.: HY-121705

Propionyl-L-carnitine

Customer Review

Based on 1 Customer Validation

Propionyl-L-carnitine is an orally active L-carnitine derivative. Propionyl-L-carnitine has a high affinity for muscle L-carnitine transferase. Propionyl-L-carnitine increases Apoptosis, Bax, and reduces NF-κB, VCAM-1, MCP-1, and survivin. Propionyl-L-carnitine activates Src kinase, Akt, induces p-AMPK and nitric oxide synthesis. Propionyl-L-carnitine alleviates cardiovascular disease, obesity, and colitis.

For research use only. We do not sell to patients.

Purity: 95.0%
CAS No.: 20064-19-1
Formula: C₁₀H₁₉NO₄
Molecular Weight:217.26

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Propionyl-L-carnitine Chemical Structure

CAS No.: 20064-19-1

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: muscular carnitine transferase^[1]

All Endogenous Metabolite Isoforms :

All Bcl-2 Family Isoforms :

All NF-κB Isoforms :

All Src Isoforms :

All Akt Isoforms :

All AMPK Isoforms :

All NO Synthase Isoforms :

In Vitro

Propionyl-L-carnitine (0-100 μM; 0-8 h) induces eNOS activation and nitric oxide synthesis in endothelial cells HAEC via PI3 and Akt kinases^[2].
Propionyl-L-carnitine (100 μM; 6-24 h) induces IκB-α mRNA, and inhibits p65 and p50 in intimal cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:

HAEC
Concentration:

25, 50, 75, 100 μM
Incubation Time:

2, 4, 6, 8 h
Result:

Increased eNOS phosphorylation and activity in a concentration- and time-dependent manner.
Increased eNOS activity by 350% at 50 μM.
Induced Akt activation.
Activated Src kinase.
Induced phosphorylation of AMPK.

In Vivo

Propionyl-L-carnitine (120 mg/kg; p.o.; daily; starting immediately after aortic injury and lasting for 15 days) reduces the relative aortic intimal volume, increases apoptosis, up-regulates Bax without changing the Bcl-2 level, and reduces NF-κB, VCAM-1, MCP-1, and survivin in rats^[3].
Propionyl-L-carnitine (30-120 mg/kg/day, p.o., drinking water) enhances wound healing and counteracts microvascular endothelial cell dysfunction in rats^[4].
Propionyl-L-carnitine (3.6 mg/mL, infused into the renal artery at the rate of 0.4 mL/min) prevents renal function deterioration due to ischemia/reperfusion in male Sprague-Dawley rats^[5].
Propionyl-L-carnitine (200 mg/kg/day, p.o., 4 weeks) corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity^[6].
Propionyl-L-carnitine (25 mg/kg, intrarectal, twice daily, for 1 week; 120 mg/kg, p.o., once daily, for 1 week) reduces intestinal damage and microvascular dysfunction in rat TNBS-induced acute and reactivated colitis^[7].
Propionyl-L-carnitine (200 mg/kg, p.o., drinking water) increases NO synthesis by enhancing eNOS expression in spontaneously hypertensive rats^[8].
Propionyl-L-carnitine (500 mg/kg, i.p., 10 successive days) prevents the progression of Cisplatin (HY-17394)-induced cardiomyopathy in a carnitine-depleted rat model^[9].
Propionyl-L-carnitine (200 mg/kg per d, p.o., 20 weeks) reduces body weight and hyperinsulinaemia in obese Zucker rats^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Wistar rats (200-225 g, 13-14 weeks old), skin flap model and full-thickness skin wound model^[4]
Dosage:

For the skin flap model, 100 mg/kg (dissolved in drinking water); for the full-thickness skin wound model, 30 mg/kg, 60 mg/kg, 120 mg/kg (dissolved in water).
Administration:

Oral gavage (p.o.), drinking water
Result:

Showed a faster blood flow recovery of the flap, an improved viability, reduced ROS production, increased NO level and iNOS expression (In the skin flap model).
Reduced the necrotic skin area after 8 days (in the skin flap model).
Had faster re-epithelialization, increased CD31⁺ capillaries, iNOS, VEGF and PlGF expression, and reduced Nox4⁺ microvessels (in the full-thickness skin wound model).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 20064-19-1
Appearance Solid
Molecular Weight 217.26
Formula C₁₀H₁₉NO₄
Color White to off-white
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : 125 mg/mL (575.35 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6028 mL

23.0139 mL

46.0278 mL

5 mM

0.9206 mL

4.6028 mL

9.2056 mL

10 mM

0.4603 mL

2.3014 mL

4.6028 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Victor Kamoen, et al. Propionyl-L-carnitine for intermittent claudication. Cochrane Database Syst Rev. 2021 Dec 26;12(12):CD010117. [Content Brief]

[2]. Ning WH, et al. Propionyl-L-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases. Vascul Pharmacol. 2013 Sep-Oct;59(3-4):76-82. [Content Brief]

[3]. Orlandi A, et al. Propionyl-L-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intimal smooth muscle cells by modulating nuclear factor-kappaB activity. J Biol Chem. 2007 Feb 16;282(7):4932-4942. [Content Brief]

[4]. Scioli MG, et al. Propionyl-L-Carnitine Enhances Wound Healing and Counteracts Microvascular Endothelial Cell Dysfunction. PLoS One. 2015 Oct 16;10(10):e0140697. [Content Brief]

[5]. Mister M, et al. Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney Int. 2002 Mar;61(3):1064-78. [Content Brief]

[6]. Mingorance C, et al. Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity. PLoS One. 2012;7(3):e34268. [Content Brief]

[7]. Scioli MG, et al. Propionyl-L-Carnitine is Efficacious in Ulcerative Colitis Through its Action on the Immune Function and Microvasculature. Clin Transl Gastroenterol. 2014 Mar 20;5(3):e55. [Content Brief]

[8]. Alvarez de Sotomayor M, et al. Effect of L-carnitine and propionyl-L-carnitine on endothelial function of small mesenteric arteries from SHR. J Vasc Res. 2007;44(5):354-64. [Content Brief]

[9]. Al-Majed AA, et al. Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res. 2006 Mar;53(3):278-86. [Content Brief]

[10]. Mingorance C, et al. Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats. Br J Nutr. 2009 Oct;102(8):1145-53. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	4.6028 mL	23.0139 mL	46.0278 mL	115.0695 mL
	5 mM	0.9206 mL	4.6028 mL	9.2056 mL	23.0139 mL
	10 mM	0.4603 mL	2.3014 mL	4.6028 mL	11.5070 mL
	15 mM	0.3069 mL	1.5343 mL	3.0685 mL	7.6713 mL
	20 mM	0.2301 mL	1.1507 mL	2.3014 mL	5.7535 mL
	25 mM	0.1841 mL	0.9206 mL	1.8411 mL	4.6028 mL
	30 mM	0.1534 mL	0.7671 mL	1.5343 mL	3.8357 mL
	40 mM	0.1151 mL	0.5753 mL	1.1507 mL	2.8767 mL
	50 mM	0.0921 mL	0.4603 mL	0.9206 mL	2.3014 mL
	60 mM	0.0767 mL	0.3836 mL	0.7671 mL	1.9178 mL
	80 mM	0.0575 mL	0.2877 mL	0.5753 mL	1.4384 mL
	100 mM	0.0460 mL	0.2301 mL	0.4603 mL	1.1507 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Propionyl-L-carnitine

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Peptide Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Peptide Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

All Endogenous Metabolite Isoforms

All Bcl-2 Family Isoforms

All NF-κB Isoforms

All Src Isoforms

All Akt Isoforms

All AMPK Isoforms

All NO Synthase Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs